Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib versus standard multikinase inhibitor therapy in RET-mutated medullary thyroid cancer
2020-005269-15Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Medullary Thyroid Cancer (MTC) comparing Pralsetinib with Investigator's choice standard of care (2 arms). Primary endpoint: Progression-free survival by Blinded Independent Central Review. Started Dec 2021; status: terminated.
02
Drugs
pralsetinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2020-005269-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005269-15.